[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2021000128A - SUBSTITUTE OXOPYRIDINE DERIVATIVES - Google Patents

SUBSTITUTE OXOPYRIDINE DERIVATIVES

Info

Publication number
DOP2021000128A
DOP2021000128A DO2021000128A DO2021000128A DOP2021000128A DO P2021000128 A DOP2021000128 A DO P2021000128A DO 2021000128 A DO2021000128 A DO 2021000128A DO 2021000128 A DO2021000128 A DO 2021000128A DO P2021000128 A DOP2021000128 A DO P2021000128A
Authority
DO
Dominican Republic
Prior art keywords
substitute
oxopyridine derivatives
derivatives
thromboembolic
oxopyridine
Prior art date
Application number
DO2021000128A
Other languages
Spanish (es)
Inventor
Lang Dieter
Matthias Gericke Kersten
Anlauf Sonja
Schäfer Martina
Tersteegen Adrian
Heitmeier Stefan
Hillisch Alexander
Röhrig Susanne
Ellerbrock Pascal
Neubauer Thomas
Essig Sebastian
Stampfauss Jan
Wang Hongping
Meng Xianghai
Meier Katharina
Zou Zengqiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DOP2021000128A publication Critical patent/DOP2021000128A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a derivados de oxopiridina sustituidos y a procesos para su preparación, y también a su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular trastornos vasculares, preferentemente trastornos trombóticos o tromboembólicos y/o complicaciones trombóticas o tromboembólicas.The invention relates to substituted oxopyridine derivatives and processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and / or thrombotic complications or thromboembolic.

DO2021000128A 2018-12-21 2021-06-18 SUBSTITUTE OXOPYRIDINE DERIVATIVES DOP2021000128A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
DOP2021000128A true DOP2021000128A (en) 2021-09-30

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000128A DOP2021000128A (en) 2018-12-21 2021-06-18 SUBSTITUTE OXOPYRIDINE DERIVATIVES

Country Status (22)

Country Link
EP (1) EP3898633A1 (en)
JP (1) JP2022514303A (en)
KR (1) KR20210106504A (en)
CN (1) CN113474348A (en)
AR (1) AR117435A1 (en)
AU (1) AU2019407909B2 (en)
BR (1) BR112021009435A2 (en)
CA (1) CA3124220A1 (en)
CL (1) CL2021001613A1 (en)
CO (1) CO2021007908A2 (en)
CR (1) CR20210342A (en)
DO (1) DOP2021000128A (en)
EA (1) EA202191764A1 (en)
EC (1) ECSP21043895A (en)
IL (1) IL283990A (en)
JO (1) JOP20210161A1 (en)
MA (1) MA54521A (en)
MX (1) MX2021007508A (en)
PE (1) PE20211790A1 (en)
SG (1) SG11202104384PA (en)
TW (1) TW202039510A (en)
WO (1) WO2020127504A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111770917B (en) * 2018-03-15 2023-09-26 拜耳股份公司 Process for the preparation of two compounds
CN114105881B (en) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 Platelet aggregation inhibitor, and preparation method and application thereof
CN117015535A (en) 2021-03-09 2023-11-07 拜耳公司 (4S)-2 4 -chloro-4-ethyl-7 3 -fluoro-3 5 -methoxy-3 2 5-dioxo-1 4 - (trifluoromethyl) -3 2 H-6-aza-3 (4, 1) -pyridine-1 (1) - [1,2,3]Triazole-2 (1, 2), 7 (1) -5-diphenylheptane-7 4 Crystalline forms of formamide
US20240173310A1 (en) 2021-03-09 2024-05-30 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN114560754A (en) * 2022-02-25 2022-05-31 滁州学院 Preparation method of alkyl alcohol
WO2024223790A1 (en) * 2023-04-28 2024-10-31 Basf Se Use of alkyl 4-alkoxypentanoates as aroma chemicals
CN116874469B (en) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 Oxo-pyridine compound, intermediate, preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (en) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituted indazoles
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
EP2978425B1 (en) 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (en) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
CN105555767B (en) 2013-07-23 2018-03-23 拜耳制药股份公司 Substituted oxo pyridine derivative and its purposes as factor XI, plasma thromboplastin antecedent A/ blood plasma
CA2928867A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197889B1 (en) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CA2961981A1 (en) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197891B1 (en) * 2014-09-24 2018-11-21 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
WO2016046159A1 (en) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2722423T3 (en) * 2014-09-24 2019-08-12 Bayer Pharma AG Substituted oxopyridine derivatives
ES2722425T3 (en) 2014-09-24 2019-08-12 Bayer Pharma AG (2H) -2-Oxopyridines as inhibitors of factor XIa for the treatment of thrombotic diseases
US20190119213A1 (en) * 2015-03-19 2019-04-25 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (en) 2015-07-09 2021-01-31 Bayer Pharma AG Substituted oxopyridine derivatives
US20180250280A1 (en) 2015-09-04 2018-09-06 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
MA54521A (en) 2022-03-30
JP2022514303A (en) 2022-02-10
EA202191764A1 (en) 2021-10-22
KR20210106504A (en) 2021-08-30
CR20210342A (en) 2021-08-09
JOP20210161A1 (en) 2023-01-30
BR112021009435A2 (en) 2021-08-17
TW202039510A (en) 2020-11-01
CO2021007908A2 (en) 2021-07-19
SG11202104384PA (en) 2021-05-28
CL2021001613A1 (en) 2021-12-03
EP3898633A1 (en) 2021-10-27
CN113474348A (en) 2021-10-01
PE20211790A1 (en) 2021-09-09
CA3124220A1 (en) 2020-06-25
IL283990A (en) 2021-07-29
AR117435A1 (en) 2021-08-04
WO2020127504A1 (en) 2020-06-25
AU2019407909A1 (en) 2021-05-27
ECSP21043895A (en) 2021-07-30
AU2019407909B2 (en) 2023-05-25
MX2021007508A (en) 2021-08-05

Similar Documents

Publication Publication Date Title
DOP2021000128A (en) SUBSTITUTE OXOPYRIDINE DERIVATIVES
ECSP18001308A (en) SUBSTITUTE OXOPYRIDINE DERIVATIVES
ECSP20072258A (en) Substituted derivatives of the carboxamide dihydropyrazolo pyrazine
CR20150476A (en) OXOPYRIDINE SUBSTITUTED DERIVATIVES AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
UY35344A (en) OESTRA-1,3,5 (10), 16-TETRAENE-3-CARBOXAMIDS
CO2019002361A2 (en) 1-arylnaphthyridine-3-substituted 7-carboxamides and their use
UY37671A (en) N-ARILETIL-2-AMINOQUINOLIN-4-SUBSTITUTED CARBOXAMIDS AND THEIR USE
ECSP24024658A (en) SUBSTITUTED S-ALANINATE DERIVATIVES
CO2019011285A2 (en) N-arylethyl-2-arylquinoline -4-substituted carboxamides and their use
NI201500168A (en) SUBSTITUTE BENZOXAZOLES
WO2016092377A3 (en) Composition containing glucosamine, calcium fructoborate and vitamin d for preventing and/or treating disorders associated with inflammatory joint diseases and spine diseases